Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

2.760 +0.040 (+1.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abcellera Biologics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
3 Stock Gems Hiding in the Nasdaq
If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks. 
Via InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: AbCellera Biologics Q4 Earnings
Via Benzinga
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
The 7 Best Penny Stocks to Buy in Q2 2024
Discover seven penny stocks to buy primed for significant gains in Q2 2024. Don't miss out on these picks or your portfolio could suffer. 
Via InvestorPlace
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February
This article is a recap of how 7 artificial intelligence stock categories did in February, and YTD, compared to each other to help you make prudent investment decisions accordingly. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
ABCL earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
These 9 AI Stock Categories Performed From +18% To -4% Last Week
A synopsis of the performances of each of the 9 different artificial intelligence stock categories last week, and YTD, along with a description of what makes up each category and the stocks included in... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
From AbCellera Biologics Inc.
Via Business Wire
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Healthcare stocks have underperformed in 2023, but that is expected to change this year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.